US7119184B2
(en)
*
|
1991-08-12 |
2006-10-10 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
JP4148662B2
(ja)
*
|
2000-08-10 |
2008-09-10 |
第一三共株式会社 |
ヌクレオシド及びオリゴヌクレオチド類縁体を含有する核酸試薬及び医薬
|
JP4151751B2
(ja)
*
|
1999-07-22 |
2008-09-17 |
第一三共株式会社 |
新規ビシクロヌクレオシド類縁体
|
DE60119562T2
(de)
|
2000-10-04 |
2007-05-10 |
Santaris Pharma A/S |
Verbesserte synthese von purin-blockierten nukleinsäure-analoga
|
GB0114719D0
(en)
*
|
2001-06-15 |
2001-08-08 |
Glaxo Group Ltd |
Compound
|
WO2003033696A1
(fr)
*
|
2001-10-18 |
2003-04-24 |
Sankyo Company, Limited |
Compose antisens vegf
|
DK2354148T3
(da)
*
|
2002-02-13 |
2013-10-14 |
Takeshi Imanishi |
Nukleosidanaloger og oligonukleotiderivate omfattende nukleotidanalog deraf
|
US20040219565A1
(en)
|
2002-10-21 |
2004-11-04 |
Sakari Kauppinen |
Oligonucleotides useful for detecting and analyzing nucleic acids of interest
|
CA2504694C
(en)
|
2002-11-05 |
2013-10-01 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
AU2003290596B2
(en)
|
2002-11-05 |
2011-05-12 |
Isis Pharmaceuticals, Inc. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
DK1569661T3
(da)
*
|
2002-11-18 |
2010-01-11 |
Santaris Pharma As |
Antisense design
|
AU2013201786B2
(en)
*
|
2002-11-18 |
2015-04-02 |
Roche Innovation Center Copenhagen A/S |
Amino-LNA, thio-LNA and alpha-L-oxy-LN
|
JP5132025B2
(ja)
*
|
2002-11-19 |
2013-01-30 |
第一三共株式会社 |
新規2’,5’−オリゴアデニル酸類縁体
|
TWI347948B
(en)
|
2002-11-19 |
2011-09-01 |
Sankyo Co |
Novel 2',5'-oligoadenylic acid compositions
|
US7902160B2
(en)
|
2002-11-25 |
2011-03-08 |
Masafumi Matsuo |
ENA nucleic acid drugs modifying splicing in mRNA precursor
|
US20050089889A1
(en)
|
2003-06-20 |
2005-04-28 |
Ramsing Niels B. |
Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same
|
EP2530157B1
(de)
|
2003-07-31 |
2016-09-28 |
Regulus Therapeutics Inc. |
Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von miRNAs
|
EP1661905B9
(de)
*
|
2003-08-28 |
2012-12-19 |
IMANISHI, Takeshi |
Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
|
US20050053981A1
(en)
*
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
US7480382B2
(en)
*
|
2003-09-30 |
2009-01-20 |
Microsoft Corporation |
Image file container
|
GB0324854D0
(en)
*
|
2003-10-24 |
2003-11-26 |
Expresson Biosystems Ltd |
App/ena antisense
|
EP1688493B1
(de)
*
|
2003-11-07 |
2008-08-13 |
Daiichi Sankyo Company, Limited |
Verfahren zum nachweis von genetischem polymorphismus
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
WO2005116207A1
(ja)
*
|
2004-05-28 |
2005-12-08 |
Sankyo Company, Limited |
テロメラーゼ阻害enaオリゴヌクレオチド
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
WO2006059507A1
(ja)
*
|
2004-11-30 |
2006-06-08 |
Sankyo Company, Limited |
11β-HSD1アンチセンス化合物
|
US20090264635A1
(en)
*
|
2005-03-25 |
2009-10-22 |
Applera Corporation |
Methods and compositions for depleting abundant rna transcripts
|
DK1931780T3
(en)
|
2005-08-29 |
2016-01-25 |
Regulus Therapeutics Inc |
Antisense-forbindelser med forøget anti-microrna-aktivitet
|
US9862770B2
(en)
|
2005-10-19 |
2018-01-09 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
US20100226884A1
(en)
|
2009-01-20 |
2010-09-09 |
Immunomedics, Inc. |
Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
|
US8883162B2
(en)
*
|
2005-10-19 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
EP3000480A1
(de)
|
2005-12-01 |
2016-03-30 |
ProNAi Therapeutics, Inc. |
Krebstherapien und dabei verwendete pharmazeutische zusammensetzungen
|
KR101404374B1
(ko)
*
|
2005-12-09 |
2014-06-09 |
도꾸리쯔교세이호징 리가가쿠 겐큐소 |
핵산의 복제방법 및 신규한 인공 염기쌍
|
CN103301475B
(zh)
*
|
2005-12-28 |
2016-08-03 |
斯克里普斯研究所 |
药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
|
DK1984381T3
(da)
|
2006-01-27 |
2010-11-01 |
Isis Pharmaceuticals Inc |
6-modificerede bicycliske nukleinsyreanaloger
|
EP2388328A1
(de)
|
2006-01-27 |
2011-11-23 |
Isis Pharmaceuticals, Inc. |
Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von microRNAs
|
WO2007143315A2
(en)
|
2006-05-05 |
2007-12-13 |
Isis Pharmaceutical, Inc. |
Compounds and methods for modulating expression of pcsk9
|
EP2505648A1
(de)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Verbindungen und Verfahren zur Modulation der Expression von PTP1B
|
CA2651453C
(en)
|
2006-05-11 |
2014-10-14 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
JP5665317B2
(ja)
|
2006-10-18 |
2015-02-04 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
アンチセンス化合物
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
CA2670563A1
(en)
*
|
2006-11-27 |
2008-06-05 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
WO2008104978A2
(en)
*
|
2007-02-28 |
2008-09-04 |
Quark Pharmaceuticals, Inc. |
Novel sirna structures
|
US8278425B2
(en)
|
2007-05-30 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
DK2173760T4
(en)
|
2007-06-08 |
2016-02-08 |
Isis Pharmaceuticals Inc |
Carbocyclic bicyclic nukleinsyreanaloge
|
EP2173358B1
(de)
*
|
2007-06-22 |
2015-10-21 |
Isis Pharmaceuticals, Inc. |
Doppelsträngige zusammensetzungen mit unterschiedlich modifizierten strängen zur verwendung bei der genmodulation
|
US8278283B2
(en)
|
2007-07-05 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
6-disubstituted or unsaturated bicyclic nucleic acid analogs
|
CA2700953A1
(en)
|
2007-10-02 |
2009-04-09 |
Amgen Inc. |
Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
|
AU2008306455C1
(en)
|
2007-10-03 |
2014-04-17 |
Quark Pharmaceuticals, Inc. |
Novel siRNA structures
|
US8546556B2
(en)
*
|
2007-11-21 |
2013-10-01 |
Isis Pharmaceuticals, Inc |
Carbocyclic alpha-L-bicyclic nucleic acid analogs
|
US20110105584A1
(en)
*
|
2007-12-12 |
2011-05-05 |
Elena Feinstein |
Rtp80il sirna compounds and methods of use thereof
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
WO2009090639A2
(en)
*
|
2008-01-15 |
2009-07-23 |
Quark Pharmaceuticals, Inc. |
Sirna compounds and methods of use thereof
|
WO2009100320A2
(en)
|
2008-02-07 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
US10131904B2
(en)
|
2008-02-11 |
2018-11-20 |
Rxi Pharmaceuticals Corporation |
Modified RNAi polynucleotides and uses thereof
|
EP2268316A4
(de)
*
|
2008-03-20 |
2011-05-25 |
Quark Pharmaceuticals Inc |
Neue sirna-verbindungen zur hemmung von rtp801
|
DK2285819T3
(da)
|
2008-04-04 |
2013-12-02 |
Isis Pharmaceuticals Inc |
Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
|
WO2009144704A2
(en)
*
|
2008-04-15 |
2009-12-03 |
Quark Pharmaceuticals, Inc. |
siRNA COMPOUNDS FOR INHIBITING NRF2
|
WO2009149182A1
(en)
|
2008-06-04 |
2009-12-10 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small rna targeting of gene promoters
|
EP2293800B1
(de)
|
2008-06-06 |
2016-10-05 |
Quark Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von ohrerkrankungen
|
TWI455944B
(zh)
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
JP2011529686A
(ja)
|
2008-07-29 |
2011-12-15 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
ポリグルタミンタンパク質発現の選択的阻害
|
AU2009275387B2
(en)
*
|
2008-08-25 |
2010-07-08 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
AU2009293658A1
(en)
|
2008-09-22 |
2010-03-25 |
James Cardia |
Reduced size self-delivering RNAi compounds
|
US8501805B2
(en)
|
2008-09-24 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-L-bicyclic nucleosides
|
JP6128732B2
(ja)
*
|
2008-10-03 |
2017-05-17 |
クルナ・インコーポレーテッド |
アポリポタンパク質−a1に対する天然アンチセンス転写物の抑制によるアポリポタンパク質−a1関連疾患の治療
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
KR101761424B1
(ko)
*
|
2008-12-04 |
2017-07-26 |
큐알엔에이, 인크. |
Vegf에 대한 천연 안티센스 전사체의 억제에 의해 맥관 내피 성장 인자(vegf) 관련된 질환의 치료
|
RU2620970C2
(ru)
|
2008-12-04 |
2017-05-30 |
КьюРНА,Инк., |
Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро
|
CN102361985B
(zh)
|
2008-12-04 |
2017-06-20 |
库尔纳公司 |
通过抑制肿瘤抑制基因的天然反义转录物治疗肿瘤抑制基因相关性疾病
|
WO2010080554A1
(en)
|
2008-12-17 |
2010-07-15 |
Avi Biopharma, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
WO2010080452A2
(en)
|
2008-12-18 |
2010-07-15 |
Quark Pharmaceuticals, Inc. |
siRNA COMPOUNDS AND METHODS OF USE THEREOF
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
ES2560107T3
(es)
|
2009-02-12 |
2016-02-17 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
|
CA2755409C
(en)
|
2009-03-16 |
2019-04-30 |
Joseph Collard |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
CA2755404C
(en)
|
2009-03-17 |
2020-03-24 |
Joseph Collard |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
WO2010124231A2
(en)
|
2009-04-24 |
2010-10-28 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
DE102009019476A1
(de)
*
|
2009-05-04 |
2010-11-11 |
Biametrics Marken Und Rechte Gmbh |
Wiedererkennbarer Träger für optische Meßverfahren
|
CN106237345A
(zh)
|
2009-05-06 |
2016-12-21 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
US20120046236A1
(en)
|
2009-05-06 |
2012-02-23 |
Opko Curna Llc |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
CA3185821A1
(en)
|
2009-05-08 |
2010-11-11 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
CA2762369C
(en)
|
2009-05-18 |
2021-12-28 |
Joseph Collard |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
WO2010135695A2
(en)
|
2009-05-22 |
2010-11-25 |
Curna, Inc. |
TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
|
ES2618576T3
(es)
|
2009-05-28 |
2017-06-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico
|
JP2012529430A
(ja)
|
2009-06-08 |
2012-11-22 |
クォーク ファーマシューティカルズ インコーポレーティッド |
慢性腎臓疾患の治療方法
|
CN102612560B
(zh)
|
2009-06-16 |
2017-10-17 |
库尔纳公司 |
通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病
|
EP2443237B1
(de)
|
2009-06-16 |
2017-02-22 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem kollagengen durch hemmung des natürlichen antisense-transkripts zu einem kollagengens
|
US8859515B2
(en)
|
2009-06-24 |
2014-10-14 |
Curna, Inc. |
Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
KR101801407B1
(ko)
|
2009-07-24 |
2017-11-24 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
|
CA2769665A1
(en)
|
2009-08-05 |
2011-02-10 |
Opko Curna, Llc |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
EP2462153B1
(de)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexosenukleinsäureanaloga
|
US9044493B2
(en)
|
2009-08-11 |
2015-06-02 |
Curna, Inc. |
Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
|
KR101805213B1
(ko)
|
2009-08-21 |
2017-12-06 |
큐알엔에이, 인크. |
Chip에 대한 천연 안티센스 전사체의 억제에 의한 “hsp70-상호작용 단백질(chip)의 c-말단” 관련된 질환의 치료
|
JP5964232B2
(ja)
|
2009-08-25 |
2016-08-03 |
カッパーアールエヌエー,インコーポレイテッド |
‘iqモチーフ含有gtpアーゼ活性化タンパク質’(iqgap)に対する天然アンチセンス転写産物の阻害によるiqgap関連疾患の治療
|
CA2775111C
(en)
|
2009-09-25 |
2019-12-31 |
Opko Curna, Llc |
Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
|
US20120220649A1
(en)
|
2009-10-30 |
2012-08-30 |
Daiichi Sankyo Company, Limited |
Modified double-stranded polynucleotide
|
WO2011053994A1
(en)
|
2009-11-02 |
2011-05-05 |
Alnylam Pharmaceuticals, Inc. |
Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
|
WO2011072091A1
(en)
|
2009-12-09 |
2011-06-16 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the cns
|
EP3012324A3
(de)
|
2009-12-09 |
2016-07-06 |
Nitto Denko Corporation |
Modulation der hsp47-expression
|
KR101823702B1
(ko)
|
2009-12-16 |
2018-01-30 |
큐알엔에이, 인크. |
막 결합 전사 인자 펩티다제, 부위 1(mbtps1)에 대한 천연 안티센스 전사체의 억제에 의한 mbtps1 관련 질환의 치료
|
RU2609631C2
(ru)
|
2009-12-23 |
2017-02-02 |
Курна, Инк. |
Лечение заболеваний, связанных с фактором роста гепатоцитов (фрг), посредством ингибирования природного антисмыслового транскрипта к фрг
|
KR101793753B1
(ko)
|
2009-12-23 |
2017-11-03 |
큐알엔에이, 인크. |
커플링방지 단백질 2(ucp2)에 대한 천연 안티센스 전사체의 저해에 의한 ucp2 관련 질환의 치료
|
RU2611186C2
(ru)
|
2009-12-29 |
2017-02-21 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63
|
US8921334B2
(en)
|
2009-12-29 |
2014-12-30 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
|
JP6083735B2
(ja)
|
2009-12-31 |
2017-02-22 |
カッパーアールエヌエー,インコーポレイテッド |
インスリン受容体基質2(irs2)および転写因子3(tfe3)に対する天然アンチセンス転写物の阻害によるインスリン受容体基質2(irs2)関連疾患の治療
|
JP5886757B2
(ja)
|
2010-01-04 |
2016-03-16 |
カッパーアールエヌエー,インコーポレイテッド |
インターフェロン調節因子8(irf8)に対する天然アンチセンス転写物の阻害によるインターフェロン調節因子8(irf8)関連疾患の治療
|
RU2612161C2
(ru)
|
2010-01-06 |
2017-03-02 |
Курна, Инк. |
Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
WO2011085102A1
(en)
|
2010-01-11 |
2011-07-14 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
KR101854926B1
(ko)
|
2010-01-11 |
2018-05-04 |
큐알엔에이, 인크. |
성 호르몬 결합 글로불린 (shbg)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (shbg) 관련된 질환의 치료
|
CA2786568A1
(en)
|
2010-01-25 |
2011-07-28 |
Curna, Inc. |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
WO2011097388A1
(en)
|
2010-02-03 |
2011-08-11 |
Alnylam Pharmaceuticals, Inc. |
Selective inhibition of polyglutamine protein expression
|
CA2790506A1
(en)
|
2010-02-22 |
2011-08-25 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
EP2842577A1
(de)
|
2010-03-12 |
2015-03-04 |
Daiichi Sankyo Company, Limited |
Verfahren zur Proliferation von Cardiomyozyten mithilfe von Mikro-RNA
|
US9193752B2
(en)
|
2010-03-17 |
2015-11-24 |
Isis Pharmaceuticals, Inc. |
5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
CN105131067B
(zh)
|
2010-03-24 |
2019-02-19 |
雷克西制药公司 |
皮肤与纤维化症候中的rna干扰
|
US9080171B2
(en)
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
CN106074591B
(zh)
|
2010-03-24 |
2020-01-14 |
菲奥医药公司 |
眼部症候中的rna干扰
|
CA2795145C
(en)
|
2010-04-02 |
2019-01-22 |
Curna, Inc. |
Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
|
WO2011127337A2
(en)
|
2010-04-09 |
2011-10-13 |
Opko Curna Llc |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
CN103154014B
(zh)
|
2010-04-28 |
2015-03-25 |
Isis制药公司 |
修饰核苷、其类似物以及由它们制备的寡聚化合物
|
JP2013525483A
(ja)
|
2010-05-03 |
2013-06-20 |
カッパーアールエヌエー,インコーポレイテッド |
サーチュイン(sirt)に対する天然アンチセンス転写物の阻害によるサーチュイン(sirt)関連疾患の治療
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
RU2620978C2
(ru)
|
2010-05-26 |
2017-05-30 |
Курна, Инк. |
Лечение заболеваний, связанных с метионинсульфоксидредуктазой а (msra), путем ингибирования природного антисмыслового транскрипта гена msra
|
EP2576783B1
(de)
|
2010-05-26 |
2017-11-29 |
CuRNA, Inc. |
Behandlung von durch atonal homolog 1 (atoh1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für atoh1
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2585596B1
(de)
|
2010-06-23 |
2020-12-30 |
CuRNA, Inc. |
Behandlung von scna-vermittelten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen scna
|
RU2611190C2
(ru)
|
2010-07-14 |
2017-02-21 |
Курна, Инк. |
Лечение заболеваний, связанных с геном dlg, путем ингибирования природного антисмыслового транскрипта гена dlg
|
EP2412724A1
(de)
|
2010-07-29 |
2012-02-01 |
Centre National de la Recherche Scientifique (C.N.R.S) |
Regulierung der Glypican-4-Aktivität zur Modulierung des Schicksals von Stammzellen und Verwendungen davon
|
EP2625274B1
(de)
|
2010-10-06 |
2017-07-19 |
CuRNA, Inc. |
Behandlung sialidase-4-(neu4)-vermittelter erkrankungen durch hemmung des natürlichen antisense-transkripts gegen neu4
|
EP2630241B1
(de)
|
2010-10-22 |
2018-10-17 |
CuRNA, Inc. |
Behandlung von alpha-l-iduronidase (idua)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen idua
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
WO2012071238A2
(en)
|
2010-11-23 |
2012-05-31 |
Opko Curna Llc |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
US8987226B2
(en)
|
2010-12-02 |
2015-03-24 |
Daiichi Sankyo Company, Limited |
Modified single-stranded polynucleotides
|
EP3467109A1
(de)
|
2011-02-08 |
2019-04-10 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
|
WO2012118910A2
(en)
|
2011-03-03 |
2012-09-07 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating lung disease and injury
|
US9796979B2
(en)
|
2011-03-03 |
2017-10-24 |
Quark Pharmaceuticals Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
CA2828544A1
(en)
|
2011-03-03 |
2012-09-07 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
TWI658830B
(zh)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Hsp47表現調控強化用類視色素脂質體
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
CA2838588C
(en)
|
2011-06-09 |
2021-09-14 |
Curna, Inc. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
BR112013032223A2
(pt)
*
|
2011-06-15 |
2016-12-20 |
Grifols Therapeutics Inc |
molécula de ácido nucleico isolada, e, composição
|
WO2013022966A1
(en)
|
2011-08-11 |
2013-02-14 |
Isis Pharmaceuticals, Inc. |
Linkage modified gapped oligomeric compounds and uses thereof
|
WO2013036403A1
(en)
|
2011-09-06 |
2013-03-14 |
Curna, Inc. |
TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
|
WO2013040429A1
(en)
|
2011-09-14 |
2013-03-21 |
Rana Therapeutics Inc. |
Multimeric oligonucleotide compounds
|
MX356814B
(es)
|
2011-11-03 |
2018-06-13 |
Quark Pharmaceuticals Inc |
Métodos y composiciones para neuroprotección.
|
JP2015502365A
(ja)
|
2011-12-12 |
2015-01-22 |
オンコイミューニン,インコーポレイティド |
オリゴヌクレオチドのイン−ビボ送達
|
US9737480B2
(en)
|
2012-02-06 |
2017-08-22 |
President And Fellows Of Harvard College |
ARRDC1-mediated microvesicles (ARMMs) and uses thereof
|
US20150031750A1
(en)
|
2012-03-15 |
2015-01-29 |
The Scripps Research Institute |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
WO2013148283A1
(en)
|
2012-03-30 |
2013-10-03 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
|
US9221864B2
(en)
|
2012-04-09 |
2015-12-29 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2013159108A2
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
CA2873809A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating gene expression
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
EA201492116A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии mecp2
|
JP2015523854A
(ja)
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Smn遺伝子ファミリー発現を調節するための組成物及び方法
|
JP2013256452A
(ja)
*
|
2012-06-11 |
2013-12-26 |
Kawaken Fine Chem Co Ltd |
メラニン産生抑制剤とその組成物
|
US9738681B2
(en)
|
2012-06-18 |
2017-08-22 |
Daiichi Sankyo Company, Limited |
Intermediate for production of nucleoside analog and method for producing the same
|
EP2897633B1
(de)
|
2012-09-18 |
2020-01-01 |
UTI Limited Partnership |
Behandlung von schmerzen durch hemmung von usp5-deubiquitinase
|
WO2014059353A2
(en)
|
2012-10-11 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2014071406A1
(en)
|
2012-11-05 |
2014-05-08 |
Pronai Therapeutics, Inc. |
Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
|
CN105143470B
(zh)
|
2013-02-28 |
2020-06-09 |
德克萨斯大学系统董事会 |
用于将癌症分类为易感于tmepai定向疗法以及治疗所述癌症的方法
|
WO2014143158A1
(en)
|
2013-03-13 |
2014-09-18 |
The Broad Institute, Inc. |
Compositions and methods for labeling of agents
|
US9273349B2
(en)
|
2013-03-14 |
2016-03-01 |
Affymetrix, Inc. |
Detection of nucleic acids
|
MX2015012621A
(es)
|
2013-03-14 |
2016-05-31 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de tau.
|
US9822418B2
(en)
|
2013-04-22 |
2017-11-21 |
Icahn School Of Medicine At Mount Sinai |
Mutations in PDGFRB and NOTCH3 as causes of autosomal dominant infantile myofibromatosis
|
JP6995478B2
(ja)
|
2013-05-01 |
2022-01-14 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Hbvおよびttr発現を調節するための組成物および方法
|
TWI702046B
(zh)
|
2013-07-19 |
2020-08-21 |
美商Ionis製藥公司 |
用於調節τ蛋白表現之組合物
|
US10174328B2
(en)
|
2013-10-04 |
2019-01-08 |
Translate Bio Ma, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
WO2015075166A1
(en)
|
2013-11-22 |
2015-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of a bacterial infection
|
US10934550B2
(en)
|
2013-12-02 |
2021-03-02 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer
|
EP3099798B1
(de)
|
2014-01-29 |
2018-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Oligonukleotide und methoden zur inhibierung oder verminderung von bakteriellen biofilmen
|
EP3126499B1
(de)
|
2014-04-01 |
2020-06-24 |
Biogen MA Inc. |
Zusammensetzungen zur modulierung der sod-1 -expression
|
EP3137476B1
(de)
|
2014-04-28 |
2019-10-09 |
Ionis Pharmaceuticals, Inc. |
Verbindungsmodifizierte oligomerverbindungen
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
SG11201608502TA
(en)
|
2014-05-01 |
2016-11-29 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating complement factor b expression
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
|
JP6562517B2
(ja)
*
|
2014-07-31 |
2019-08-21 |
国立大学法人大阪大学 |
架橋型ヌクレオシドおよびヌクレオチド
|
IL234246A0
(en)
|
2014-08-21 |
2014-11-30 |
Omrix Biopharmaceuticals Ltd |
Stabilized thrombin
|
EP3188799B1
(de)
|
2014-09-05 |
2022-07-06 |
Phio Pharmaceuticals Corp. |
Verfahren zur behandlung von alterung und hauterkrankungen mit auf tyr oder mmp1 gerichteten nukleinsäuren
|
AU2015327836B2
(en)
|
2014-10-03 |
2021-07-01 |
Cold Spring Harbor Laboratory |
Targeted augmentation of nuclear gene output
|
US9816080B2
(en)
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
AU2015364508A1
(en)
|
2014-12-18 |
2017-07-06 |
Alnylam Pharmaceuticals, Inc. |
ReversirTM compounds
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
JP6983752B2
(ja)
|
2015-07-06 |
2021-12-17 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
スーパーオキシドディスムターゼ1(sod1)を標的とする核酸分子
|
WO2017015109A1
(en)
|
2015-07-17 |
2017-01-26 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
US20190055550A1
(en)
|
2015-08-24 |
2019-02-21 |
Roche Innovation Center Copenhagen A/S |
LNA-G Process
|
KR20220105174A
(ko)
|
2015-10-09 |
2022-07-26 |
유니버시티 오브 사우스앰톤 |
유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
|
JP2018531037A
(ja)
|
2015-10-19 |
2018-10-25 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
長い非コードrnaを標的とする減少したサイズの自己送達型核酸化合物
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
WO2017079442A1
(en)
|
2015-11-04 |
2017-05-11 |
Icahn School Of Medicine At Mount Sinai |
Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
|
BR112018007633A2
(pt)
|
2015-11-12 |
2018-11-06 |
F. Hoffmann-La Roche Ag |
oligonucleotídeos para indução de expressão de ube3a paterna
|
EP3389670A4
(de)
|
2015-12-04 |
2020-01-08 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur behandlung von brustkrebs
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
EP3933041B1
(de)
|
2015-12-14 |
2024-01-31 |
Cold Spring Harbor Laboratory |
Antisense-oligomere zur behandlung von autosomaldominierender geistiger behinderung
|
TWI794662B
(zh)
|
2016-03-14 |
2023-03-01 |
瑞士商赫孚孟拉羅股份公司 |
用於降低pd-l1表現之寡核苷酸
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
CA3013799A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating keap1
|
WO2017178656A1
(en)
|
2016-04-14 |
2017-10-19 |
Roche Innovation Center Copenhagen A/S |
TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
|
US11246868B2
(en)
|
2016-04-26 |
2022-02-15 |
Icahn School Of Medicine At Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
EP3471781A4
(de)
|
2016-06-17 |
2020-05-06 |
Ionis Pharmaceuticals, Inc. |
Modulierung der gys1-expression
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
WO2018002105A1
(en)
|
2016-07-01 |
2018-01-04 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
EP3507367A4
(de)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
Cyclisches dinukleotidverbindungen mit eingeschlossenen nukleinsäuren und verwendungen davon
|
WO2018013525A1
(en)
|
2016-07-11 |
2018-01-18 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
BR112019004911A2
(pt)
|
2016-09-14 |
2019-06-25 |
Janssen Biopharma Inc |
oligonucleotídeos modificados e métodos de uso
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
WO2018067546A1
(en)
|
2016-10-03 |
2018-04-12 |
President And Fellows Of Harvard College |
Delivery of therapeutic rnas via arrdc1-mediated microvesicles
|
JP7033591B2
(ja)
|
2016-11-11 |
2022-03-10 |
ロシュ イノベーション センター コペンハーゲン エーエス |
治療用オリゴヌクレオチドの捕捉および検出
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
WO2018123925A1
(ja)
|
2016-12-28 |
2018-07-05 |
第一三共株式会社 |
アルポート症候群治療薬
|
US10450565B2
(en)
|
2017-01-10 |
2019-10-22 |
Arrowhead Pharmaceuticals, Inc. |
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
|
US20200216845A1
(en)
|
2017-01-13 |
2020-07-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
US20190345496A1
(en)
|
2017-01-13 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
US20190338286A1
(en)
|
2017-01-13 |
2019-11-07 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
WO2018130584A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
EP3568479A1
(de)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense-oligonukleotide zur modulierung der nfkb1-expression
|
US11180756B2
(en)
|
2017-03-09 |
2021-11-23 |
Ionis Pharmaceuticals |
Morpholino modified oligomeric compounds
|
US11963974B2
(en)
|
2017-03-10 |
2024-04-23 |
National Center For Child Health And Development |
Antisense oligonucleotide and composition for prevention or treatment of glycogen storage disease type Ia
|
US11377468B2
(en)
|
2017-03-10 |
2022-07-05 |
Lakewood Amedex, Inc. |
Antimicrobial compounds, compositions, and uses thereof
|
US11795192B2
(en)
|
2017-03-10 |
2023-10-24 |
Lakewood Amedex, Inc. |
Antimicrobial compounds, compositions, and uses thereof
|
CN110612143B
(zh)
*
|
2017-03-10 |
2021-07-02 |
莱克伍德阿美达克斯股份有限公司 |
抗微生物化合物、组合物及其用途
|
CN110650742A
(zh)
|
2017-03-17 |
2020-01-03 |
国立大学法人千叶大学 |
使用经结构强化的S-TuD的新的癌症治疗方法
|
WO2018212271A1
(ja)
|
2017-05-18 |
2018-11-22 |
国立大学法人京都大学 |
脊髄小脳変性症36型の予防又は治療用組成物
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
US20200172903A1
(en)
|
2017-07-05 |
2020-06-04 |
Osaka University |
ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION
|
US11028390B2
(en)
|
2017-07-10 |
2021-06-08 |
Osaka University |
Antisense oligonucleotide controlling expression amount of TDP-43 and use thereof
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
AU2018318231A1
(en)
|
2017-08-18 |
2020-02-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
CN111278991B
(zh)
|
2017-08-25 |
2022-04-01 |
斯托克制药公司 |
用于治疗病况和疾病的反义寡聚体
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
CN111527207B
(zh)
|
2017-09-14 |
2024-04-26 |
詹森生物制药有限公司 |
GalNAc衍生物
|
JP2021502059A
(ja)
|
2017-10-13 |
2021-01-28 |
ロシュ イノベーション センター コペンハーゲン エーエス |
部分的に立体定義されたオリゴヌクレオチドのサブライブラリーを使用することによる、アンチセンスオリゴヌクレオチドの、改良された立体定義されたホスホロチオエートオリゴヌクレオチド変異体を同定するための方法
|
EP3645723A1
(de)
|
2017-10-16 |
2020-05-06 |
H. Hoffnabb-La Roche Ag |
Nukleinsäuremolekül zur reduktion von papd5- und papd7-mrna zur behandlung von hepatitis-b-infektionen
|
EP3697904A1
(de)
|
2017-10-17 |
2020-08-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kombinationsbehandlung für zystische fibrose
|
WO2019111791A1
(ja)
*
|
2017-12-07 |
2019-06-13 |
第一三共株式会社 |
ジストロフィン遺伝子のイントロンリテンションを解消するアンチセンスオリゴヌクレオチド
|
US20200385714A1
(en)
|
2017-12-11 |
2020-12-10 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
CN111512160B
(zh)
|
2017-12-21 |
2024-04-09 |
豪夫迈·罗氏有限公司 |
Htra1 rna拮抗剂的伴随诊断
|
US20200339982A1
(en)
|
2017-12-22 |
2020-10-29 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
JP7476101B2
(ja)
|
2017-12-22 |
2024-04-30 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホロジチオアートヌクレオシド間結合を含むギャップマーオリゴヌクレオチド
|
CN111448316A
(zh)
|
2017-12-22 |
2020-07-24 |
罗氏创新中心哥本哈根有限公司 |
新的硫代亚磷酰胺
|
WO2019137883A1
(en)
|
2018-01-10 |
2019-07-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating pias4 expression
|
EP3737759A1
(de)
|
2018-01-12 |
2020-11-18 |
Roche Innovation Center Copenhagen A/S |
Alpha-synnuclein-antisense-oligonukleotide und verwendungen davon
|
CA3087966A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
WO2019137974A1
(en)
|
2018-01-12 |
2019-07-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating gsk3b expression
|
WO2019140231A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
WO2019141656A1
(en)
|
2018-01-17 |
2019-07-25 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
JP2021511029A
(ja)
|
2018-01-18 |
2021-05-06 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Srebp1を標的とするアンチセンスオリゴヌクレオチド
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
MX2020008290A
(es)
|
2018-02-09 |
2020-09-25 |
Genentech Inc |
Oligonucleotidos para modular la expresion de tmem106b.
|
SG11202007652UA
(en)
|
2018-02-21 |
2020-09-29 |
Bristol Myers Squibb Co |
Camk2d antisense oligonucleotides and uses thereof
|
JP6884268B2
(ja)
|
2018-03-09 |
2021-06-09 |
第一三共株式会社 |
糖原病Ia型治療薬
|
AU2019233612A1
(en)
|
2018-03-13 |
2020-09-10 |
Janssen Pharmaceutica Nv |
Modified oligonucleotides for use in treatment of tauopathies
|
EP3775208A1
(de)
|
2018-04-05 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Verwendung von fubp1-inhibitoren zur behandlung von hepatitis-b-virus-infektionen
|
WO2019215066A1
(en)
|
2018-05-07 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Quality control of lna oligonucleotide therapeutics using massively parallel sequencing
|
US20220125823A1
(en)
|
2018-05-07 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
WO2019215175A1
(en)
|
2018-05-08 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
EP3793685A1
(de)
|
2018-05-18 |
2021-03-24 |
F. Hoffmann-La Roche AG |
Pharmazeutische zusammensetzungen zur behandlung von krankheiten im zusammenhang mit mikro-rna
|
WO2019224172A1
(en)
|
2018-05-25 |
2019-11-28 |
Roche Innovation Center Copenhagen A/S |
Novel process for making allofuranose from glucofuranose
|
EP3802824A1
(de)
|
2018-06-05 |
2021-04-14 |
F. Hoffmann-La Roche AG |
Oligonukleotide zur modulierung der atxn2-expression
|
AU2019285147A1
(en)
|
2018-06-13 |
2020-12-03 |
Daiichi Sankyo Company, Limited |
Myocardial dysfunction therapeutic agent
|
US20210260002A1
(en)
|
2018-06-18 |
2021-08-26 |
University Of Rochester |
Methods of treating schizophrenia and other neuropsychiatric disorders
|
US20220062378A1
(en)
|
2018-06-21 |
2022-03-03 |
University Of Rochester |
Methods of treating or inhibiting onset of huntington's disease
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
PE20220013A1
(es)
|
2018-07-03 |
2022-01-11 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de tau
|
EP3819378A4
(de)
|
2018-07-04 |
2022-09-14 |
Aichi Medical University |
Oligonukleotide zur kontrolle von tau-splicing und deren verwendungen
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
MX2021000404A
(es)
|
2018-07-13 |
2021-03-25 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de rtel1.
|
CA3105705A1
(en)
|
2018-07-31 |
2020-02-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
EP3830101A1
(de)
|
2018-07-31 |
2021-06-09 |
Roche Innovation Center Copenhagen A/S |
Oligonukleotide mit einer phosphordithioat-internukleosid-verknüpfung
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
WO2020038968A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Microrna-134 biomarker
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
US20220160870A1
(en)
|
2018-08-28 |
2022-05-26 |
Roche Innovation Center Copenhagen A/S |
Neoantigen engineering using splice modulating compounds
|
EP3620519A1
(de)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Verwendung von isolierten extrazellulären vesikeln aus milch zur oralen verabreichung von oligonukleotiden
|
TW202028465A
(zh)
|
2018-09-28 |
2020-08-01 |
美商阿尼拉製藥公司 |
甲狀腺素運載蛋白(TTR)iRNA組成物及其治療或預防TTR相關眼部疾病之使用方法
|
JP2022503733A
(ja)
|
2018-10-17 |
2022-01-12 |
レイクウッド アメディックス、インコーポレイテッド |
口腔粘膜炎を治療するための方法および組成物
|
WO2020089260A1
(en)
|
2018-11-01 |
2020-05-07 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting tia1
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
EA202191342A1
(ru)
|
2018-11-15 |
2021-08-10 |
Айонис Фармасьютикалз, Инк. |
Модуляторы экспрессии irf5
|
JP7467457B2
(ja)
|
2018-11-22 |
2024-04-15 |
ロシュ イノベーション センター コペンハーゲン エーエス |
立体的に規定されたオリゴヌクレオチドの合成における活性化物質としてのピリジニウム塩
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
WO2020109344A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Occular administration device for antisense oligonucleotides
|
AU2019396450A1
(en)
|
2018-12-11 |
2021-06-24 |
University Of Rochester |
Methods of treating schizophrenia and other neuropsychiatric disorders
|
JP2022514648A
(ja)
|
2018-12-21 |
2022-02-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Card9を標的とするアンチセンスオリゴヌクレオチド
|
WO2020152303A1
(en)
|
2019-01-25 |
2020-07-30 |
F. Hoffmann-La Roche Ag |
Lipid vesicle for oral drug delivery
|
SG11202107399WA
(en)
|
2019-01-31 |
2021-08-30 |
Ionis Pharmaceuticals Inc |
Modulators of yap1 expression
|
EP3923962A2
(de)
|
2019-02-13 |
2021-12-22 |
University of Rochester |
Gennetzwerke, die die remyelinisierung des menschlichen gehirns vermitteln
|
JP2022521512A
(ja)
|
2019-02-20 |
2022-04-08 |
ロシュ イノベーション センター コペンハーゲン エーエス |
新規ホスホルアミダイト
|
EP3927826A1
(de)
|
2019-02-20 |
2021-12-29 |
Roche Innovation Center Copenhagen A/S |
Phosphonoacetat-gapmer-oligonukleotide
|
CN113474633A
(zh)
|
2019-02-26 |
2021-10-01 |
罗氏创新中心哥本哈根有限公司 |
寡核苷酸配制方法
|
US11279932B2
(en)
|
2019-02-27 |
2022-03-22 |
Ionis Pharmaceuticals, Inc. |
Modulators of MALAT1 expression
|
WO2020178258A1
(en)
|
2019-03-05 |
2020-09-10 |
F. Hoffmann-La Roche Ag |
Intracellular targeting of molecules
|
KR20210141554A
(ko)
|
2019-03-21 |
2021-11-23 |
코디악 바이오사이언시즈, 인크. |
세포외 소포 접합체 및 이의 용도
|
EP3967328A4
(de)
|
2019-03-29 |
2022-12-28 |
Sysmex Corporation |
Neue künstliche nukleinsäure, verfahren zu ihrer herstellung und ihre verwendung
|
EA202192733A1
(ru)
|
2019-04-03 |
2022-03-14 |
Бристол-Маерс Сквибб Компани |
Антисмысловые олигонуклеотиды angptl2 и их применения
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
WO2020201339A1
(en)
|
2019-04-04 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating atxn2 expression
|
CN113661168A
(zh)
|
2019-04-16 |
2021-11-16 |
罗氏创新中心哥本哈根有限公司 |
用于制备核苷酸p(v)单体的新方法
|
EP3962918A1
(de)
|
2019-04-30 |
2022-03-09 |
Roche Innovation Center Copenhagen A/S |
Neuartiges verfahren zur herstellung von rheniumchelatierten mag3-oligonukleotiden
|
MX2021013418A
(es)
|
2019-05-03 |
2021-12-10 |
Dicerna Pharmaceuticals Inc |
Moleculas inhibidoras de acido nucleico bicatenario con cadenas de sentido acortadas.
|
US20220211743A1
(en)
|
2019-05-17 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
EP3980539A1
(de)
|
2019-06-06 |
2022-04-13 |
F. Hoffmann-La Roche AG |
Gegen atxn3 gerichtete antisense-oligonukleotide
|
WO2020256084A1
(ja)
*
|
2019-06-19 |
2020-12-24 |
ヤマサ醤油株式会社 |
架橋型ヌクレオシド中間体の結晶及びその製造方法、並びに架橋型ヌクレオシドアミダイトの製造方法
|
WO2020262184A1
(ja)
|
2019-06-26 |
2020-12-30 |
神戸天然物化学株式会社 |
ミオスタチン遺伝子のmRNAの産生を抑制する核酸医薬
|
EP3997225A1
(de)
|
2019-07-10 |
2022-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur behandlung von epilepsie
|
WO2021010301A1
(ja)
|
2019-07-12 |
2021-01-21 |
第一三共株式会社 |
DUX4 pre-mRNAのスプライシングを変化させるアンチセンスオリゴヌクレオチド
|
CA3144687A1
(en)
|
2019-07-18 |
2021-01-21 |
Steven A. Goldman |
Cell-type selective immunoprotection of cells
|
WO2021021673A1
(en)
|
2019-07-26 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
CA3147701A1
(en)
|
2019-08-14 |
2021-02-18 |
Codiak Biosciences, Inc. |
Extracellular vesicles with antisense oligonucleotides targeting kras
|
WO2021030780A1
(en)
|
2019-08-14 |
2021-02-18 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting cebp/beta
|
EP4013876A1
(de)
|
2019-08-14 |
2022-06-22 |
Codiak BioSciences, Inc. |
Extrazelluläre vesikel mit nlrp3-antagonist
|
WO2021030768A1
(en)
|
2019-08-14 |
2021-02-18 |
Codiak Biosciences, Inc. |
Extracellular vesicles with stat3-antisense oligonucleotides
|
CA3145924A1
(en)
|
2019-08-14 |
2021-02-18 |
Yi Zhang |
Extracellular vesicle linked to molecules and uses thereof
|
AU2020328611A1
(en)
|
2019-08-14 |
2022-03-03 |
Lonza Sales Ag |
Extracellular vesicle-aso constructs targeting STAT6
|
CN114555621A
(zh)
|
2019-08-15 |
2022-05-27 |
Ionis制药公司 |
键修饰的寡聚化合物及其用途
|
EP4029520A4
(de)
|
2019-09-10 |
2024-05-29 |
Daiichi Sankyo Company, Limited |
Galnac-oligonukleotid-konjugat für die gezielte abgabe an die leber und verfahren zum produzieren desselben
|
EP4034247A1
(de)
|
2019-09-25 |
2022-08-03 |
Codiak BioSciences, Inc. |
Sting-agonisten mit exosomen zur behandlung von neuroimmunologischen erkrankungen
|
WO2021074657A1
(en)
|
2019-10-17 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination treatment for cystic fibrosis
|
TW202128704A
(zh)
|
2019-10-18 |
2021-08-01 |
日商第一三共股份有限公司 |
雙環亞磷醯胺之製造方法
|
CN111109591A
(zh)
|
2019-10-25 |
2020-05-08 |
新疆红旗坡农业发展集团有限公司 |
肠道微生态高效重建型苹果酵素及加工技术
|
WO2021092145A1
(en)
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
CA3160329A1
(en)
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
JP2023506550A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ. ホフマン-ラ ロシュ エージー. |
B型肝炎ウイルス感染症を処置するためのsbds阻害剤の使用
|
CN114829599A
(zh)
|
2019-12-19 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途
|
EP4077671A1
(de)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Verwendung von saraf-inhibitoren zum behandeln von hepatitis-b-virus-infektionen
|
JP2023506546A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ. ホフマン-ラ ロシュ エージー. |
B型肝炎ウイルス感染症を処置するためのsept9阻害剤の使用
|
CN115516091A
(zh)
|
2019-12-19 |
2022-12-23 |
豪夫迈·罗氏有限公司 |
Cops3抑制剂用于治疗乙型肝炎病毒感染的用途
|
EP4077672A1
(de)
|
2019-12-20 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Verbesserte oligonukleotide zur hemmung der scn9a-expression
|
AU2020415322A1
(en)
|
2019-12-24 |
2022-06-16 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combination of antiviral agents targeting HBV and/or an immune modulator for treatment of HBV
|
EP4081639A1
(de)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmazeutische kombination eines therapeutischen oligonucleotids gegen hbv und eines tlr7-agonisten zur behandlung von hbv
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
CN115176010A
(zh)
|
2020-02-28 |
2022-10-11 |
豪夫迈·罗氏有限公司 |
用于调节cd73外显子7剪接的寡核苷酸
|
EP4119167A1
(de)
|
2020-03-11 |
2023-01-18 |
BioComber Co. Ltd |
Einsträngiges nukleinsäuremolekül zur induzierung von 1-rahmenverschiebung und zusammensetzung
|
WO2021184021A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting pmp22
|
WO2021184020A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Methods of treating neuroinflammation
|
BR112022019752A2
(pt)
|
2020-03-31 |
2022-11-16 |
Janssen Biopharma Inc |
Síntese de oligonucleotídeos e compostos relacionados
|
EP4150084A1
(de)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Komplementkomponente-4-inhibitoren zur behandlung neurologischer erkrankungen und zugehörige zusammensetzungen, systeme und verfahren zur verwendung davon
|
CA3173647A1
(en)
|
2020-05-11 |
2021-11-18 |
Isabel AZNAREZ |
Opa1 antisense oligomers for treatment of conditions and diseases
|
JP2023527684A
(ja)
|
2020-05-11 |
2023-06-30 |
ジェネンテック, インコーポレイテッド |
神経疾患を治療するための補体成分c1s阻害剤、並びにそれを使用する関連組成物、システム及び方法
|
EP4150085A1
(de)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Komplementkomponente c1r-inhibitoren zur behandlung einer neurologischen erkrankung sowie zugehörige zusammensetzungen, systeme und verfahren zur verwendung davon
|
EP4150083A1
(de)
|
2020-05-13 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Oligonukleotidagonisten zum targeting von progranulin
|
US20230193269A1
(en)
|
2020-05-22 |
2023-06-22 |
Boehringer Ingelheim International Gmbh |
Oligonucleotides for splice modulation of card9
|
EP4162047A1
(de)
|
2020-06-09 |
2023-04-12 |
Roche Innovation Center Copenhagen A/S |
Guanosinanaloga zur verwendung in therapeutischen polynukleotiden
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
JP2023534557A
(ja)
|
2020-07-23 |
2023-08-09 |
エフ. ホフマン-ラ ロシュ アーゲー |
Rna結合タンパク質部位を標的とするオリゴヌクレオチド
|
CA3187977A1
(en)
|
2020-07-28 |
2022-02-03 |
Knc Laboratories Co., Ltd. |
Antisense oligonucleotide inducing exon skipping of angiotensin converting enzyme 2 gene
|
JP2023538630A
(ja)
|
2020-08-21 |
2023-09-08 |
エフ. ホフマン-ラ ロシュ アーゲー |
B型肝炎ウイルス感染症を処置するためのa1cf阻害剤の使用
|
WO2022043531A1
(en)
*
|
2020-08-28 |
2022-03-03 |
Janssen Sciences Ireland Unlimited Company |
7'-substituted 2'-o-4'-c-ethylene-bridged nucleic acid (ena) monomers and uses thereof
|
EP4219517A1
(de)
|
2020-09-25 |
2023-08-02 |
Riken Genesis Co., Ltd. |
Neuartige künstliche nukleinsäure, verfahren zur herstellung davon und verwendung davon
|
WO2022076596A1
(en)
|
2020-10-06 |
2022-04-14 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
WO2022117747A2
(en)
|
2020-12-03 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
WO2022117745A1
(en)
|
2020-12-03 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
WO2022122613A1
(en)
|
2020-12-08 |
2022-06-16 |
F. Hoffmann-La Roche Ag |
Novel synthesis of phosphorodithioate oligonucleotides
|
EP4263831A1
(de)
|
2020-12-18 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Antisense oligonukleotide zum targeting von progranulin
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ. ホフマン-ラ ロシュ アーゲー |
Xbp1を標的とするオリゴヌクレオチド
|
WO2022147223A2
(en)
|
2020-12-31 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
2'-modified nucleoside based oligonucleotide prodrugs
|
JP2024501857A
(ja)
|
2020-12-31 |
2024-01-16 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ
|
KR20230128050A
(ko)
*
|
2020-12-31 |
2023-09-01 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 근긴장성 이영양증을 치료하기위한 그의 용도
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 rtel1 表現之增強型寡核苷酸
|
CA3207944A1
(en)
|
2021-02-17 |
2022-08-25 |
Ajay Verma |
Extracellular vesicle-nlrp3 antagonist
|
EP4294456A1
(de)
|
2021-02-17 |
2023-12-27 |
Lonza Sales AG |
Extrazelluläre vesikel, die über einen optimierten linker mit einem biologisch aktiven molekül verbunden sind und eine verankerungseinheit
|
JPWO2022181532A1
(de)
|
2021-02-26 |
2022-09-01 |
|
|
EP4314016A1
(de)
|
2021-03-31 |
2024-02-07 |
Entrada Therapeutics, Inc. |
Zyklische zellen penetrierende peptide
|
KR20230166101A
(ko)
|
2021-04-01 |
2023-12-06 |
론자 세일즈 아게 |
세포외 소포 조성물
|
KR20240012425A
(ko)
|
2021-05-10 |
2024-01-29 |
엔트라다 테라퓨틱스, 인크. |
세포내 치료제를 위한 조성물 및 방법
|
WO2022240721A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
|
EP4337261A2
(de)
|
2021-05-10 |
2024-03-20 |
Entrada Therapeutics, Inc. |
Zusammensetzungen und verfahren zur modulation des spleissens von mrna
|
CN117441018A
(zh)
|
2021-06-08 |
2024-01-23 |
豪夫迈·罗氏有限公司 |
寡核苷酸颗粒蛋白前体激动剂
|
KR20240038967A
(ko)
|
2021-06-23 |
2024-03-26 |
엔트라다 테라퓨틱스, 인크. |
Cug 반복을 표적화하기 위한 안티센스 화합물 및 방법
|
EP4367237A2
(de)
|
2021-07-09 |
2024-05-15 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai-verbindungen zur zns-verabreichung
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
CA3226887A1
(en)
|
2021-07-21 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Metabolic disorder-associated target gene irna compositions and methods of use thereof
|
CA3229305A1
(en)
|
2021-08-16 |
2023-02-23 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
EP4389893A1
(de)
|
2021-08-21 |
2024-06-26 |
Takeda Pharmaceutical Company Limited |
Peptid-wirkstoff-konjugat, das an den menschlichen transferrin-rezeptor bindet
|
AU2022339769A1
(en)
|
2021-09-01 |
2024-03-28 |
Entrada Therapeutics, Inc. |
Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
|
AR127158A1
(es)
|
2021-09-29 |
2023-12-27 |
Hoffmann La Roche |
Oligonucléotido antisentido para la edición de arn asociado a enfermedades de poliglutamina
|
IL311864A
(en)
|
2021-10-15 |
2024-06-01 |
Alnylam Pharmaceuticals Inc |
IRNA compositions for extrahepatic administration and methods of using them
|
WO2023078883A1
(en)
|
2021-11-03 |
2023-05-11 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating apolipoprotein e4 expression
|
AU2022384619A1
(en)
|
2021-11-11 |
2024-04-11 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combinations for treatment of hbv
|
WO2023104693A1
(en)
|
2021-12-07 |
2023-06-15 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
WO2023111210A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Combination of oligonucleotides for modulating rtel1 and fubp1
|
WO2023111336A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Oligonucleotide gba agonists
|
WO2023117738A1
(en)
|
2021-12-20 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
WO2023150553A1
(en)
|
2022-02-01 |
2023-08-10 |
University Of Rochester |
Gpr17 promoter-based targeting and transduction of glial progenitor cells
|
WO2023152369A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
|
AR128558A1
(es)
|
2022-02-21 |
2024-05-22 |
Hoffmann La Roche |
Oligonucleótido antisentido
|
US11931421B2
(en)
|
2022-04-15 |
2024-03-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
WO2023217890A1
(en)
|
2022-05-10 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting cfp-elk1 intergene region
|
WO2023220744A2
(en)
|
2022-05-13 |
2023-11-16 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
TW202409276A
(zh)
|
2022-05-18 |
2024-03-01 |
瑞士商赫孚孟拉羅股份公司 |
改良之靶向rna結合蛋白位點的寡核苷酸
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
WO2023242324A1
(en)
|
2022-06-17 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for targeting progranulin
|
WO2024006999A2
(en)
|
2022-06-30 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
EP4332221A1
(de)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose-nukleinsäure-antisense-oligonukleotide und verfahren dafür
|
WO2024052403A1
(en)
|
2022-09-06 |
2024-03-14 |
F. Hoffmann-La Roche Ag |
Double-stranded rna molecule for administration to the eye
|
WO2024073732A1
(en)
|
2022-09-30 |
2024-04-04 |
Alnylam Pharmaceuticals, Inc. |
Modified double-stranded rna agents
|
US20240182561A1
(en)
|
2022-11-04 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
WO2024098061A2
(en)
|
2022-11-04 |
2024-05-10 |
Genkardia Inc. |
Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
WO2024119145A1
(en)
|
2022-12-01 |
2024-06-06 |
Camp4 Therapeutics Corporation |
Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2024126654A1
(en)
|
2022-12-14 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
CN117510564B
(zh)
*
|
2024-01-08 |
2024-03-08 |
苏州诺维康生物科技有限公司 |
一种医药中间体N2-Ac-5'-O-DMT-2'-O-炔丙基鸟苷的合成方法
|